Affiliation:
1. Department of Biotechnology, Motilal Nehru National Institute of Technology Allahabad, Prayagraj, 211004, India
Abstract
Abstract:
Colorectal cancer (CRC) is a multifaceted and heterogeneous ailment that affects the
colon or rectum of the digestive system. It is the second most commonly occurring form of cancer
and ranks third in terms of mortality rate. The progression of CRC does not occur due to a single
mutational event; rather, it is the result of the sequential and cumulative accumulation of mutations
in key driver genes of signaling pathways. The most significant signaling pathways, which have
oncogenic potential due to their deregulation, include Wnt/β-catenin, Notch, TGF-β,
EGFR/MAPK, and PI3K/AKT pathways. Numerous drug target therapies have been developed to
treat CRC using small molecule inhibitors, antibodies, or peptides. Although drug-targeted therapy
is effective in most cases, the development of resistance mechanisms in CRC has raised questions
about their efficacy. To overcome this issue, a novel approach to drug repurposing has come to
light, which utilizes already FDA-approved drugs to treat CRC. This approach has shown some
promising experimental results, making it a crucial avenue of research in the treatment of CRC.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine